Homeostasis Model Assessment (Beta Cell Function) of a Type 2 Diabetes Nigerian Population
Main Article Content
Abstract
Diabetes mellitus has been described to be a metabolic disorder characterized by the presence of hyperglycemia resulting from defective insulin secretion, action or both. This study was designed to determine serum insulin level, fasting plasma glucose and % β-cell function in treated and untreated complicated and uncomplicated diabetes subjects. Ninety subjects comprising of sixty test subjects (30 uncomplicated and 30 complicated diabetes subjects) and thirty control subjects were recruited for this study. Glucose was estimated using Glucose-Oxidase Peroxidase method, while Insulin was analyzed using ELISA. The results obtained showed thatBMI, Glucose, %βCF and insulin showed no significant difference in treated uncomplicated diabetes subjects compared to control (p>0.05). Glucose and %βCF were significantly higher (p<0.05) in untreated uncomplicated diabetes subjects compared to control, while BMI and insulin showed no significant difference (p>0.05).Glucose and %βCF were significantly higher (p<0.05) in untreated uncomplicated diabetes subjects compared to treated subjects, while insulin and BMI showed no significant difference (p>0.05).BMI, systolic blood pressure, diastolic blood pressure and insulin level were significantly higher (p<0.05) in treated complicated diabetes subjects compared to control, whereas Glucose and %βCF showed no significant difference (p>0.05). Glucose correlated positively with all parameters in untreated uncomplicated diabetes subjects. We conclude that insulin is increased, while % β-cell function is reduced in diabetes subjects especially in untreated complicated diabetes subjects. Insulin resistance and impaired β-cell function are important pathological basis for the deterioration of glucose metabolism in type 2 diabetes mellitus. Therefore, early screening and intervention for T2DM might help improve islet function and delay the progression of diabetes.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Dilworth L, Facey A, Omoruyi F. (2021). Diabetes Mellitus and Its Metabolic Complications: The Role of Adipose Tissues. International Journal of Molecular Sciences. 2021; 22(14), 7644.
II. Toren E, Burnette KS, Banerjee RR, Hunter CS and Tse HM. Partners in Crime: Beta-Cells and Autoimmune Responses Complicit in Type 1 Diabetes Pathogenesis. Frontiers in Immunology. 2021; 12:756548.
III. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, Martín C. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020; 21(17): 6275.
IV. Piche M, Tchernof A and Despres J. Obesity Phenotypes, Diabetes, and Cardiovascular Diseases. Circulation Research, 2020; 126 (11), 101-112
V. Farmaki P, Damaskos C, Garmpis N, Garmpi A, Savvanis S, Diamantis E. Complications of the Type 2 Diabetes Mellitus. Curr Cardiol Rev. 2020; 16(4):249-251.
VI. Alsaadon H, Afroz A, Karim A, Habib SH, Alramadan MJ, Billah B. and Shetty AN. Hypertension and its related factors among patients with type 2 diabetes mellitus – a multi-hospital study in Bangladesh. BMC Public Health, 2022; 198(22), 202-223.
VII. Motuma A, Gobena T, Roba KT, Berhane Y, Worku A, Regassa LD, Tolera A. Co-occurrence of hypertension and type 2 diabetes: prevalence and associated factors among Haramaya University employees in Eastern Ethiopia. Front Public Health, 2021; 11:1038694.
VIII. Feyisa BR, Tamiru A, Debelo S, Feyisa I, Tola EK, Tolesa EJ, Negeri A, Shibiru T, Galata A, Biru B. Magnitude of hypertension and its association with obesity among employees of Wallaga University, Ethiopia: a cross-sectional study. BMJ Open. 2023 13(7):e070656.
IX. Lawal Y, Bello F, Anumah FE, Bakari AG. Beta-cell function and insulin resistance among First-Degree relatives of persons with type 2 diabetes in a North-Western Nigerian Population. J Health Res Rev 2019; 6:26-30
X. Okpara HC, Nri Ezedi CA, Izuchukwu EC, Ilechukwu OU, Ene AB. Reference interval, optimal threshold value, and correlates of homeostasis model assessment of insulin resistance in healthy normal-weight adults in a Nigerian population. Niger J Med 2023; 32:166-72.
XI. Fasipe OJ, Olufisayo GA and Enikuomehin AC. Severity Grade Assessment Classifications for Both Insulin Resistance Syndrome and Status of Pancreatic Beta Cell Function in Clinical Practice Using Homeostasis Model Assessment Method Indices. Canadian Journal of Diabetes, 2020; 44 (7), 663-669.
XII. Tsai S, Yang C, Liu W and Lee C. Development and validation of an insulin resistance model for a population without diabetes mellitus and its clinical implication: a prospective cohort study. Clinical Medicine 2023; 58(1), 1-13
XIII. Park SO, Gautier JF and Chon S. Assessment of Insulin Secretion and Insulin Resistance in Human. Diabetes & Metabolism Journal, 2021; 45(5), 641-654.
XIV. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018; 34(5): 575-584.
XV. Hussain A, Noor HT, Nabu T. Evaluation of role of increased perceived stress score and body mass index in causing secondary hypertension of hepatitis C. Journal of Cardiovascular Diseases and Diagnosis, 2018; 6: 6.
XVI. Wondmkun YT. Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications. Diabetes Metab Syndr Obes. 2020; 13:3611-3616.
XVII. Gezawa ID, Uloko AE, Gwaram BA, Ibrahim DA, Ugwu ET and Mohammed IY. Pattern of Obesity Among Patients with Type 2 Diabetes at a Tertiary Healthcare Center in Northern Nigeria. Diabetes Metabolic Syndrome & Obesity, 2019; 12: 2785-2790.
XVIII. Al-Maskari MY, Al-Sharji MA, Al-Maskari AY. Higher prevalence of diabetes mellitus and abnormal lipid profiles in individuals with hepatitis C: A case-control study. Diabetes Research and Clinical Practice, 2021; 94(1), 114-118.
XIX. Odewusi O, Abbey A, Obadire O, Olaniyan O, Ogunyemi O, Omon E. Evaluation of Anticardiolipin Antibodies and Lupus Erythematosus Cell in Type 2 Diabetes Nigerian Population. Alq J Med App Sci. 2023; 6(1):193-200.
XX. Odewusi OO, Egede IS, Omon AE, Obadire SO, Sokunbi, ZT. Evaluation of Vascular Complication and Lack of Glycemic Control as Factors in the Development of Ovarian Cancer in Female Nigerian Type 2 Diabetic Population. J. Appl. Sci. Environ. Manage. 2023; 27 (10) 2315-2322
XXI. Ayogu RNB and Nwodo CJ. Epidemiological characteristics of hypertension, impaired fasting capillary glucose and their comorbidity: a retrospective cross-sectional population-based study of rural adolescents in Southeast Nigeria. British Medical Journal Open, 2021; 11(1), 481-485.
XXII. Yordanos BY, Berhanu TW and Buzuneh A. Fasting Blood Glucose Level Progression and Its Associated Factors Among Diabetic Patients Attending Treatment In North Shewa Hospitals, Oromia, Ethiopia. Research Square, 2021; 8 (2), 360-364
XXIII. Ohishi M. Hypertension with diabetes mellitus: physiology and pathology. Hypertens Res. 2018; 41(6):389-393.
XXIV. Mouri MI, Badireddy M. Hyperglycemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2023; Available from: https://www.ncbi.nlm.nih.gov/books/NBK430900/
XXV. Ali MH and Hassan AJ. Assessment of the alteration of blood indices in patients with type 2 diabetic mellitus: A cross-sectional study. Mustansiriya Medical Journal, 2019; 18: 24-30.
XXVI. Dhatariya K, Corsino L, Umpierrez GE. Management of Diabetes and Hyperglycemia in Hospitalized Patients. In: Feingold KR, Anawalt B, Blackman MR editors. South Dartmouth (MA): MDText.com, Inc. 2020; Available from: https://www.ncbi.nlm.nih.gov/books/NBK279093/
XXVII. Sheema K, Nasir R, Rukhsana G, Zahra B. Association of Insulin and Lipoprotein Level in Subjects of T2dm and Non Diabetics. Pakistan Journal of Medical and Health Sciences. 2022; 16: 53-54.
XXVIII. Dludla PV, Mabhida SE, Ziqubu K, Nkambule BB, Mazibuko-Mbeje SE, Hanser S, Basson AK, Pheiffer C, Kengne AP. Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress. World J Diabetes, 2023; 14(3):130-146.
XXIX. Khin PP, Lee JH, Jun HS. Pancreatic Beta-cell Dysfunction in Type 2 Diabetes. European Journal of Inflammation. 2023; 21: 165-169.
XXX. Wysham C, Shubrook J. Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications, Postgraduate Medicine, 2020; 132:8, 676-686
XXXI. Adams JD, Egan AM, Laurenti MC, Wismayer SD, Bailey KR, Cobelli C, Man CD and Vella A. Insulin secretion and action and the response of endogenous glucose production to a lack of glucagon suppression in nondiabetic subjects. American Journal of Physiology-Endocrinology and Metabolism, 2021; 321(5): 728-736
XXXII. Wang C, Liu Z, Zhang P, Ma X, Che K, Wang Y. The differences in homeostasis model assessment values in type 2 diabetic patients with different lengths of history of diabetes. Arch Endocrinol Metab. 2019, 63(3): 222-227.
XXXIII. Kahn SE, Yi-Chun Chen, Nathalie Esser, Austin J Taylor, Daniël H van Raalte, Sakeneh Zraika, C Bruce Verchere, The β Cell in Diabetes: Integrating Biomarkers with Functional Measures, Endocrine Reviews, 2021; 42(5): 528–583
XXXIV. Vilas-Boas EA, Almeida DC, Roma LP, Ortis F, Carpinelli AR. Lipotoxicity and β-Cell Failure in Type 2 Diabetes: Oxidative Stress Linked to NADPH Oxidase and ER Stress. Cells. 2021; 10(12): 3328.
XXXV. Forlenza GP, McVean J, Beck RW, Bauza C, Bailev R, Buckingham B, DiMeglio LA and Moran A. Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2023; 329(12):990–999.